| [1] | YOSHINO J, BAUR J A, IMAI S I. NAD+ intermediates: the biology and therapeutic potential of NMN and NR[J]. Cell Metab,2018,27(3):513-528. doi: 10.1016/j.cmet.2017.11.002 |
| [2] | HONG W Q, MO F, ZHANG Z Q, et al. Nicotinamide mononucleotide: a promising molecule for therapy of diverse diseases by targeting NAD+ metabolism[J]. Front Cell Dev Biol,2020,8:246. doi: 10.3389/fcell.2020.00246 |
| [3] | YOU Y N, GAO Y, WANG H, et al. Subacute toxicity study of nicotinamide mononucleotide via oral administration[J]. Front Pharmacol,2020,11:604404. doi: 10.3389/fphar.2020.604404 |
| [4] | MILLS K F, YOSHIDA S, STEIN L R, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice[J]. Cell Metab,2016,24(6):795-806. doi: 10.1016/j.cmet.2016.09.013 |
| [5] | SIMS C A, GUAN Y X, MUKHERJEE S, et al. Nicotinamide mononucleotide preserves mitochondrial function and increases survival in hemorrhagic shock[J]. JCI Insight,2018,3(17):120182. doi: 10.1172/jci.insight.120182 |
| [6] | MÉNDEZ-LARA K A, LETELIER N, FARRE N, et al. Nicotinamide prevents apolipoprotein B-containing lipoprotein oxidation, inflammation and atherosclerosis in apolipoprotein E-deficient mice[J]. Antioxidants,2020,9(11):1162. doi: 10.3390/antiox9111162 |
| [7] | MEHMEL M, JOVANOVIĆ N, SPITZ U. Nicotinamide riboside-the current state of research and therapeutic uses[J]. Nutrients,2020,12(6):1616. doi: 10.3390/nu12061616 |
| [8] | KISS T, NYÚL-TÓTH Á, BALASUBRAMANIAN P, et al. Nicotinamide mononucleotide (NMN) supplementation promotes neurovascular rejuvenation in aged mice: transcriptional footprint of SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic effects[J]. Geroscience,2020,42(2):527-546. doi: 10.1007/s11357-020-00165-5 |
| [9] | HONG G L, ZHENG D, ZHANG L L, et al. Administration of nicotinamide riboside prevents oxidative stress and organ injury in Sepsis[J]. Free Radic Biol Med,2018,123:125-137. doi: 10.1016/j.freeradbiomed.2018.05.073 |
| [10] | 盛杰, 张福琴, 魏萍, 等. 抗菌药物诱导内毒素释放及抗内毒素药物研究进展[J]. 医药导报, 2004, 23(4):252-253. |
| [11] | 金泓, 赖旭东, 关信民, 等. 血必净注射液在脓毒血症治疗中的疗效观察[J]. 中医临床研究, 2017, 9(36):71-73. |
| [12] | 王洪亮, 章志丹, 黄伟. 拯救脓毒症运动: 脓毒症与感染性休克治疗国际指南(2016)的解读与展望[J]. 中华重症医学电子杂志, 2017, 3(1):26-32. |
| [13] | 张含飞, 张金龙, 王振华. 抗内毒素药物的研究进展[J]. 畜牧与饲料科学, 2008, 29(1):57-60. |
| [14] | IRIE J, INAGAKI E, FUJITA M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men[J]. Endocr J,2020,67(2):153-160. doi: 10.1507/endocrj.EJ19-0313 |